BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37152370)

  • 1. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors.
    Shen J; Wei Z; Lv L; He J; Du S; Wang F; Wang Y; Ni L; Zhang X; Pan F
    Mediators Inflamm; 2023; 2023():7992140. PubMed ID: 37152370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma.
    Zhu J; Kuang J; Yang Y; Zhang L; Leng B; She R; Zou L
    Mediators Inflamm; 2023; 2023():6645476. PubMed ID: 37114236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
    Wang L; Wang Q; Li Y; Qi X; Fan X
    J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of single-cell RNA-seq and bulk RNA-seq to construct liver hepatocellular carcinoma stem cell signatures to explore their impact on patient prognosis and treatment.
    Liu L; Zhang M; Cui N; Liu W; Di G; Wang Y; Xi X; Li H; Shen Z; Gu M; Wang Z; Jiang S; Liu B
    PLoS One; 2024; 19(4):e0298004. PubMed ID: 38635528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer.
    Xu X; Wang J
    Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
    Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q
    J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
    Ding D; Wang D; Qin Y
    Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a basement membrane-related genes signature to predict prognosis, immune landscape and guide therapy in gastric cancer.
    Liu ZY; Xin L
    Medicine (Baltimore); 2023 Sep; 102(39):e35027. PubMed ID: 37773804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.
    Feng R; Cheng D; Chen X; Yang L; Wu H
    Biochem Biophys Res Commun; 2024 Jan; 692():149325. PubMed ID: 38056161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis.
    He Q; Fan B; Du P; Jin Y
    Front Cell Dev Biol; 2022; 10():806989. PubMed ID: 35356272
    [No Abstract]   [Full Text] [Related]  

  • 15. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.
    Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X
    Front Immunol; 2024; 15():1397541. PubMed ID: 38774870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.
    Tao H; Wang C; Lu C; Ma N; Zhu Y; Xuan S; Zhou X
    Genet Res (Camb); 2022; 2022():7236823. PubMed ID: 35919033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic analysis of
    Li D; Fan X; Zuo L; Wu X; Wu Y; Zhang Y; Zou F; Sun Z; Zhang W
    Ann Transl Med; 2022 Dec; 10(24):1356. PubMed ID: 36660710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma.
    Ji Z; Zhang C; Yuan J; He Q; Zhang X; Yang D; Xu N; Chu J
    PLoS One; 2024; 19(4):e0298775. PubMed ID: 38662757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
    Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
    Front Immunol; 2021; 12():676922. PubMed ID: 34335575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.